Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-12-16
2009-08-18
Desai, Rita J (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S333000
Reexamination Certificate
active
07576089
ABSTRACT:
The present invention relates to 3-cycloalkylaminopyrrolidine derivatives of the formula I:(wherein R1, R2, R3, R4, R5, R6, R7, X, Y and Z are as defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of chemokine receptors and more specifically as modulators of the CCR2 and/or CCR5 receptor. The compounds and compositions of the invention may bind to chemokine receptors, e.g., the CCR2 and/or CCR5 chemokine receptors, and are useful for treating diseases associated with chemokine, e.g., CCR2 and/or CCR5, activity, such as atherosclerosis, restenosis, lupus, organ transplant rejection and rheumatoid arthritis.
REFERENCES:
patent: 4353734 (1982-10-01), Seres et al.
patent: 5770573 (1998-06-01), Arrhenius et al.
patent: 6166037 (2000-12-01), Budhu et al.
patent: 6288084 (2001-09-01), Luly et al.
patent: 6303593 (2001-10-01), Bao et al.
patent: 6362177 (2002-03-01), Shiota et al.
patent: 6372764 (2002-04-01), Bao et al.
patent: 6410566 (2002-06-01), Shiota et al.
patent: 6432981 (2002-08-01), Finke et al.
patent: 6451842 (2002-09-01), Shiota et al.
patent: 2006/0111404 (2006-05-01), Xue et al.
patent: 2006/0252751 (2006-11-01), Xue et al.
patent: WO97/44329 (1997-11-01), None
patent: WO00/69432 (2000-11-01), None
patent: WO0069815 (2000-11-01), None
patent: WO01/10439 (2001-02-01), None
patent: WO03/092586 (2003-11-01), None
patent: WO03/093231 (2003-11-01), None
patent: WO03/093266 (2003-11-01), None
patent: WO99/25686 (2004-05-01), None
patent: WO 2004/041161 (2004-05-01), None
patent: WO 2004/041163 (2004-05-01), None
patent: WO 2004/041279 (2004-05-01), None
patent: WO 2004/041777 (2004-05-01), None
patent: WO 2004/042351 (2004-05-01), None
patent: WO 2004/050024 (2004-06-01), None
patent: WO2005/044264 (2005-05-01), None
patent: WO2005/044795 (2005-05-01), None
patent: WO2005/067502 (2005-07-01), None
patent: WO2005/070133 (2005-08-01), None
patent: WO2005/072361 (2005-08-01), None
patent: WO2005/110409 (2005-11-01), None
Jones, Maitland Organic Chemistry Norton: New York, 1997, p. 84-99.
Dorwald F. A. Side Reactions in Organic Synthesis, 2005, Wiley: VCH, Weinheim p. IX of Preface. & p. 41.
Dabrowski et. al. Tetrahedron, 2005, 6590-6595.
Clayden, J. Organolithiums: Selectivity for Organic Synthesis 2002, Pergamon: New York, Chapter 3, 111-146.
Renato Dalpozzo and Giuseppe Bartoli, “Bartoli Indole Synthesis” Current Organic Chemistry, 2005, 9, 163-178.
Parham, et. al. J. Org. Chem. 1976, 41, 1187-1191.
Jie Jack Li Name Reactions A Collection of Detailed Reaction Mechanisms “Grignard Reaction” Third Expanded Edition Springer 2006, p. 271-272.
Knochel et. al. Angew. Chem. Int. Ed. 2003, 42, 4302-4320.
Hutchins, R.O. et. al. J. Org. Chem. 1977, 42, 82-91.
Xia et. al. “Synthesis and biological evaluation of phenyl piperidine derivatives as CCR2 antagonists” Bioorganic & Medicinal Chemistry Letters 2007, 17, 5964-5968.
Wolff, Manfred E. “Burger's Medicinal Chemistry, 5ed, Part I”, John Wiley & Sons, 1995, pp. 975-977.
Banker (Modern Pharmaceutics) Banker, G.S. et al, “Modern Pharmaceutics, 3ed.”, Marcel Dekker, New York, 1996, pp. 451 and 596.
Clarissa E. Vergunst, et. al. “Modulation of CCR2 in Rheumatoid Arthritis A Double-Blind, Randomized, Placebo-Controlled Clinical Trial” Arthritis & Rheumatism 2008, 58, 1931-1939.
Database CASPLUS on STN (Columbux, OH) No. 136:200479, Kitajima et al., “Preparation of Proline Derivatives as Dipeptidyl Peplidase IV Inhibitgors and Use Thereof as Drugs,”.
Database CASPLUS on STN (Columbus, OH) No. 141:295848, Goodfellow et al., “Preparation of treatment of obesity and other disorders” (2004).
Bundgaard, “Design of prodrugs,” p. 27 and p. 33 (1988).
Han Amy Qi
Metcalf Brian W.
Robinson Darius J.
Wang Anlai
Xue Chu-Biao
Connolly Bove & Lodge & Hutz LLP
Desai Rita J
Incyte Corporation
O'Dell David K
LandOfFree
3-cycloalkylaminopyrrolidine derivatives as modulators of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 3-cycloalkylaminopyrrolidine derivatives as modulators of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3-cycloalkylaminopyrrolidine derivatives as modulators of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4076816